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Abstract 8 
Achilles tendinopathy, both insertional and non-insertional, are common cause of 9 
posterior ankle pain. Whilst many patients will improve with simple conservative 10 
measures, a proportion will go on to chronic symptoms. This study examines the 11 
outcomes of patients following Extra-Corporeal Shockwave Therapy (ESWT) plus a 12 
home exercise programme. This prospective case series study involves a total of 39 13 
patients with a mean follow-up duration of 163 days (range 65 – 385 days.) This has 14 
demonstrated significant benefits in pain, stiffness, and a range of measures of local 15 
and global function. Median (IQR) values for average self-reported pain improved from 16 
6.5/10 (IQR: 5.0 - 7.8) at baseline to 3.5/10 (2.0 - 5.1) at three-months and 2.0/10  (0.6 - 17 
4.8) at six-months for patients with insertional Achilles tendinopathy. This compares to 18 
improvements from 7.0/10 (7.0 – 8.0) at baseline to 6.0/10 (5.6-6.8) at three-months 19 
and 6.0/10 (3.0-7.0) at six-months for patients with non-insertional Achilles 20 
tendinopathy. Statistically significant improvements were seen in insertional 21 
tendinopathy across a range of outcome measures, although these were less apparent 22 
for patients with non-insertional tendinopathy. Despite these figures, there were no 23 
significant differences seen in the outcomes for patients with insertional and non-24 
insertional tendinopathy. Despite the improvements that were seen in aspects of pain 25 
and function, physical activity levels had not increased following treatment. 26 
 27 
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Introduction 36 
Rather than a single clinical entity, two distinct anatomical locations of Achilles 37 
tendinopathy are described. The commoner site is in the mid-portion of the Achilles 38 
tendon with maximal pain and swelling occurring between 2 and 7 cm proximal to the 39 
calcaneal attachment.(1) This is a relatively common condition, with an incidence in 40 
primary care of 2.35/1000 adults.(2) A less common type affects the insertion of the 41 
Achilles tendon into the posterior aspect of the calcaneus, and the two can be 42 
considered overlapping, but different, conditions.(3) One hypothesis of the causation of 43 
the mid-substance tendinopathy is from the relatively hypovascular nature of this 44 
region,(4) however an internal compression theory has also been postulated.(3) The 45 
site of the insertional Achilles tendinopathy is also a site of compression and this has 46 
again been postulated as a causative factor.(3) Achilles tendinopathy was originally 47 
considered an inflammatory process, however many studies have shown that the 48 
degenerative pathology found is more akin to a failed healing process.(1, 5-7) 49 
Neovascularity, the ingrowth of abnormal blood vessels penetrating the tendon, is often 50 
seen in chronic Achilles tendinopathy and are associated with the site of maximal 51 
tenderness and maximal thickening of the abnormal tendon.(8, 9)  Neuropathic pain 52 
may be a component of pain in patients with established Achilles tendinopathy.(10) 53 
Whilst biomechanical factors almost certainly play a part in the development of Achilles 54 
tendinopathy, it remains unclear which biomechanical faults are of primary importance 55 
leading to uncertainties about methods of improving function in those with established 56 
tendinopathy, or seeking to prevent it starting.(11) 57 
 58 
Achilles tendinopathy of both types most commonly affects active adults between 59 
the ages of 30 and 60, particularly those engaged in racquet sports, track and field, 60 
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volleyball and soccer.(9, 12-14) Runners have a 30-fold increase in Achilles 61 
tendinopathy symptoms compared to non-runners below the age of 35, with annual 62 
incidences of Achilles tendinopathy in all runners about 10%(15, 16) However about 63 
one-third of cases are not related to activity and it may be that activity is more important 64 
in provoking symptoms rather than being the cause of the condition itself in general 65 
populations.(17, 18)  In addition to activity, Achilles tendinopathy is associated with a 66 
range of other co-morbidities including obesity, the use of oral contraceptives or 67 
HRT.(19, 20)  68 
 69 
The prognosis for patients with mid-substance Achilles tendinopathy is varied. A 70 
large observational study with an eight year follow-up, showed that 84% of patients had 71 
returned to their pre-morbid activity levels and 94% of patients were asymptomatic, or 72 
had only minimal pain.(21) Most patients with Achilles tendinopathy will improve with 73 
simple conservative measures,(1, 22, 23) however surgery may be required in a quarter 74 
to a third of cases.(12, 21) Eccentric-based rehabilitation exercises have the most 75 
evidence of benefit of any of the conservative management options, and were found in 76 
several systematic reviews to be superior to either concentric-based exercise 77 
programmes, or tension-night splints.(23-26) A newer option for chronic mid-substance 78 
Achilles tendinopathy is the use of High-Volume Image-Guided Injections (HVIGI) with 79 
evidence from case series and cohort studies suggesting improvement in the majority of 80 
cases,(27, 28) but there is no published evidence yet from RCTs proving effectiveness. 81 
 82 
Insertional Achilles tendinopathy tends to be more recalcitrant than mid-83 
substance tendinopathy to a range of treatment options,(29, 30) however there is a 84 
consensus that conservative management options should be tried before surgical 85 
options are considered.(31) The evidence is limited, but there have been found to be 86 
benefits from both a modified eccentric loading programme and shockwave therapy 87 
(ESWT) as conservative options,(32, 33) Differential diagnoses of seronegative 88 
arthropathies need to be considered with patients presenting with insertional Achilles 89 
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tendinopathy symptoms, as unlike mid-substance this is a common site for seronegative 90 
disease involvement.(34-36) 91 
 92 
In patients who have failed a rehabilitation programme, Extra-Corporeal 93 
Shockwave Therapy (ESWT) have some evidence of benefit for the treatment of both 94 
insertional and non-insertional Achilles tendinopathy reported in several separate 95 
systematic reviews.(32, 33) These have shown that ESWT is more effective than 96 
eccentric loading for insertional Achilles tendinopathy, at least as good as eccentric 97 
loading for mid-substance Achilles tendinopathy, and that combining Extra-Corporeal 98 
Shockwave Therapy with eccentric-based rehabilitation gives better results than either 99 
intervention on its own.(33) However, many primary studies involve only small numbers 100 
of cases, often with relatively short duration of symptoms, and often only simple 101 
measures of pain and local function are used to record outcome rather than global 102 
markers of health and function. This study sets out to examine the outcomes following 103 
ESWT plus rehabilitation in general populations presenting to a secondary care hospital 104 
clinic with chronic Achilles tendinopathy and investigate the feasibility and usefulness of 105 
a range of different patient-rated outcome measures to give a more global view of pain 106 
and the impact that pain has on a range of domains of function. 107 
 108 
 109 
Patients/Materials and Methods 110 
Patients with chronic Achilles Tendinopathy have been treated by the author 111 
(PCW) within a single NHS Sports Medicine department in a secondary care hospital in 112 
the UK using Extra-Corporeal Shockwave Therapy (ESWT). This included patients with 113 
insertional Achilles tendinopathy, and non-insertional (sometimes referred to as mid-114 
substance) Achilles tendinopathy. Data presented here is from the period September 115 
2014 to July 2016. In line with other hospital procedures, written consent forms were 116 
used to record consent before the first session of ESWT. 117 
 118 
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Patients had sessions of ESWT performed by the same practitioner, once per 119 
week for three weeks using an “Intelect” RPW ESWT machine (DJO Global 120 
Chattanooga). Rather than a set dose, in keeping with routine clinical use and 121 
manufacturer instructions, the energy dose was controlled by the operator to a “maximal 122 
comfortably-tolerated” energy dose which was individual for different patients and varied 123 
between sessions. Both groups used manufacturer specified settings of 10.0Hz and 124 
2000 shocks per treatment. For the patients with non-insertional tendinopathy the 125 
energy doses were a mean ±SD of 2.1 ±0.3 bar for the 1st ESWT session, 2.6 ±0.3 for 126 
the 2nd, and 2.9 ±0.4 for the 3rd. For those with insertional tendinopathy the figures were 127 
2.2 ±0.4 bar / 2.7 ±0.6 / 3.1 ±0.7 respectively. Following shockwave, patients were given 128 
standardised post-procedural advice and were advised to avoid NSAIDs for the day of, 129 
and a few days after, each session of ESWT. 130 
 131 
Before undergoing shockwave therapy, patients were taught to perform a structured 132 
home exercise programme including flexibility of the lower limb, specific isometric and 133 
eccentric strengthening (through full-range for patients with non-insertional Achilles 134 
tendinopathy, but to neutral only in patients with insertional Achilles tendinopathy), as 135 
well as core stability and proprioception exercises. These exercises were prompted at 136 
each of the subsequent clinic visits to promote adherence and facilitate progression. 137 
Patients were advised that these exercises could be uncomfortable, particularly to begin 138 
with, and were taught how to manage and progress these exercises. To support the use 139 
of the home exercise programme, patients were all given written sheets discussing 140 
these exercises and reminding them of technique and how often these need to be 141 
performed for optimal benefit. 142 
 143 
 Data collection 144 
In this prospective case series study, patients with both insertional and non-145 
insertional Achilles tendinopathy were treated with undertaking shockwave therapy. 146 
Patients completed a structured questionnaire about their symptoms before treatment 147 
and at each subsequent follow-up visit. All data was collected contemporaneously. The 148 
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outcome measures included questions about pain, as well as a range of validated 149 
Patient-Rated Outcome Measures (PROMs). This included ones about specific Achilles 150 
and foot/ankle function (VISA-A, and Foot-Ankle Ability Measure (FAAM measures of 151 
global function (EQ-5D-5L) and a questionnaire that examined measures of anxiety and 152 
depression symptoms (Hospital Anxiety and Depression Scale – HADS). In addition, the 153 
short-form (7-day recall) version of the International Physical Activity Questionnaire 154 
(IPAQ) was used to quantify levels of physical activity. These measures were used to 155 
examine different aspects of functioning following the ESWT procedure. Table 1 156 
displays information for each of the PROMs used. 157 
 158 
Patients were followed up at six-week, three-months and six-months following 159 
ESWT.  160 
 161 
Based on prior literature base and clinical rationale, the primary outcome measure 162 
was a change in average pain (as recorded on a 0-10 scale) between baseline and 163 
three-months post-ESWT, with the remainder of the outcome measures studied being 164 
secondary measures to this. All data was recorded prospectively. 165 
 166 
 Ethical considerations 167 
In line with local policy, the ESWT procedure was registered with the hospital’s New 168 
Intervention Procedure Group (NIPAG) and data are recorded here in the format of a 169 
service evaluation project and audit. Patients were informed of the use of the 170 
questionnaires that they self-completed, consented for data useage, and all data was 171 
anonymized prior to use. 172 
 173 
 Statistical analysis 174 
Data was recorded prospectively at baseline, and on an on-going basis at clinic 175 
follow-up and collated into an Excel spreadsheet (MS Excel from MS Office 2011, 176 
version 14.5.7) and analysed in SPSS (IBM SPSS Statistics, version 22). From this 177 
dataset the majority of the outcome measures are scale data.  Comparisons were made 178 
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between the baseline data and data from the six-week, the three-month, and where 179 
data was present the six-month follow-up appointments. As the sample sizes were 180 
small, the Shapiro-Wilk test was used to assess normality and as the majority of the 181 
data was found to be not normally distributed the majority of the analysis was performed 182 
with non-parametric tests, typically the Wilcoxon Signed-Rank Test to look at pre/post 183 
differences within groups, and the Mann-Whitney test to compare subjects between 184 
groups. Statistical significance was set at p<0.05 185 
 186 
 187 
Results 188 
 189 
Data was obtained for a total of 39 patients during the study period; 30 were for 190 
patients with insertional Achilles tendinopathy, 9 were for patients with non-insertional 191 
(mid-substance) Achilles tendinopathy. Patients with insertional tendinopathy tended to 192 
be slightly older and with a longer duration of symptoms pre-ESWT, but this difference 193 
did not reach statistical significance. There was a mean follow up of 163 days (minimum 194 
65, maximum 385 days.) During this period, 6/30 (23%) of the subjects with insertional 195 
Achilles tendinopathy required further intervention for their symptoms, compared to 4/9 196 
(44%) of those with non-insertional Achilles tendinopathy, however this difference was 197 
not found to be significant (p=0.414) The baseline demographics and baseline PROMs 198 
are displayed in Table 2, with median and interquartile range (IQR) values used as the 199 
majority of the data was found to be non-parametric. There were no statistically 200 
significant differences between members of the two anatomical sites for any of the 201 
baseline parameters studied.  202 
 203 
Subjects were reviewed at 6 weeks, 3-months and 6-months to assess progress. 204 
This information is displayed for patients with insertional Achilles tendinopathy (Table 3) 205 
and non-insertional Achilles tendinopathy (Table 4). Data was not available for all 206 
patients at all time periods, either due to missed, postponed or cancelled appointments, 207 
or patients not reaching that specific time-period within the data collection period. 208 
 209 
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All patients tolerated all three sessions of shockwave therapy with no more than 210 
mild discomfort which was transitory. No significant complications were reported from 211 
patients treated. 212 
 213 
For subjects with insertional Achilles tendinopathy, self-reported “average” pain 214 
changed from a median of 6.5/10 (IQR: 5.0-7.8) at baseline, to 5.0/10 (3.5-5.0) at 6-215 
weeks, 3.5/10 (2.0-5.21) at 3-months, and 2.0/10 (0.6-4.8) at 6-months. (Interquartile 216 
ranges are also displayed in table 3 for clarity.) All of these follow-up periods improved 217 
from baseline to a statistically significant extent. In addition, many of the other 218 
parameters studied also improved at follow-up. This included markers of potential 219 
neuropathic pain (PainDETECT) which improved significantly from a median of 15.0 at 220 
baseline to 10.5 at 3-months and 9.5 at 6-months, as well as Achilles/ankle function 221 
questionnaires (VISA-A and the FAAM-ADL) both of which improved significantly at all 222 
time-points studied. Despite these improvements in pain and function seen, no 223 
consistent correlating improvements in overall levels of physical activity were seen 224 
using the short-form IPAQ. Furthermore, markers of global health or mental health 225 
functioning (EQ-5D and HAD) did not change significantly at follow-up compared to 226 
baseline. The specific values for the different PROMs used for patients with insertional 227 
Achilles tendinopathy are displayed in table 3, with an asterisk (*) indicating a statistical 228 
significant change (p<0.05) from baseline figures. Figures displayed are median (IQR)  229 
 230 
Median values for self-reported “average pain” in subjects with non-insertional 231 
Achilles tendinopathy changed from 7.0/10 to 6.0/10 at 6-weeks (p=0.068), to 6.0/10 at 232 
3-months (p=0.075), and to 6.0/10 at 6-months (p=0.109). None of these differences in 233 
self-reported average pain reached statistical significance, nor did any changes in self-234 
reported “worst pain” or “stiffness”, except at 3-months with a statistically significant 235 
improvement in “worst pain” from 9.0 at baseline to 8.0 at 3-months. Examining the 236 
remaining PROMs, the only value which reached a statistically significant difference 237 
was the VISA-A, improving from 24% at baseline to 44% at 3-months which reached 238 
statistical significance only at 3-months, but not at 6-weeks or 6-months. both at 3 239 
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months compared to baseline. The other marker of foot & ankle function, the FAAM did 240 
not alter significantly at any time point studied for patients with non-insertional 241 
tendinopathy. Similar to those with insertional tendinopathy, the markers of global health 242 
(ED-5D), mental health functioning (HAD), or physical activity (short-form IPAQ) did not 243 
differ significantly at the follow-up time points studied, compared to baseline. The 244 
specific values for the different PROMs used are displayed in table 4 for patients with 245 
non-insertional Achilles tendinopathy, with an asterisk (*) indicating a statistical 246 
significant change (p<0.05) from baseline figures. Figures displayed are median (IQR) 247 
 248 
To compare effectiveness for patients with insertional versus non-insertional 249 
tendinopathy, direct comparison in several specific PROMs was made using any 250 
changes from baseline to 3-months, which was the time period with the greatest 251 
proportion of data and the primary outcome period of interest. This form of analysis also 252 
takes account of any missing data at this time-point, either from patients not attending 253 
follow-up appointments, or those that had not yet reached that particular time-period 254 
post-procedure. Overall, no significant difference was seen in the changes in any of the 255 
parameters studied between subjects with either insertional or non-insertional Achilles 256 
tendinopathy. Figures from this are displayed in table 5, with figures shown median 257 
values (IQR) and a positive value representing an improvement in each score at three-258 
months from baseline levels. 259 
 260 
In addition to the measures discussed above, patients were asked to self-select 261 
at each appointment which of the stages of a Roles and Maudsley score best 262 
represented their current situation. This is a 1-4 categorical system, with a lower score 263 
indicating a better outcome at that point. 1 = “I have no symptoms or minimal symptoms 264 
now”, 2 = I have some symptoms, but these are significantly improved from before the 265 
treatment, 3 = “I have some ongoing symptoms, but these are somewhat better from 266 
before the treatment”, 4 = “My symptoms are no better, or worse than before the 267 
treatment” Overall there were no significant differences at any of the time points in the 268 
Roles & Maudsley score between subject with insertional and non-insertional Achilles 269 
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tendinopathy. These values are displayed in table 6, with figures shown being median 270 
(IQR) 271 
 272 
 273 
Discussion 274 
 275 
Overall, beneficial results were obtained for patients with insertional and non-276 
insertional Achilles tendinopathy following a combination of Extra-Corporeal Shockwave 277 
Therapy and a home rehabilitation. This study has been able to show improvements in 278 
a wide range of different patient-rated outcome measures. One of the strengths of this 279 
study is the use of different outcome measures to assess pain, function, mood and 280 
activity and this has shown improvements in some, but not all domains. Although 281 
causality of benefit cannot be shown from this study design, the overall results here are 282 
in keeping with other published evidence demonstrating benefit from Extra-Corporeal 283 
Shockwave Therapy and which may reduce the need for other treatments including 284 
surgical intervention. 285 
 286 
Based on a review of the literature and to the best knowledge of the author, this 287 
is the first paper to directly compare a group of patients with non-insertional and 288 
insertional Achilles tendinopathy to explore any differences between outcomes from 289 
these two similar, but distinct, conditions. From the comparisons between patients with 290 
insertional and non-insertional Achilles tendinopathy, there was a suggestion that 291 
patients with insertional tendinopathy received greater benefits. However, the 292 
differences seen, did not reach statistical significance, however these may have been 293 
affected by the limited numbers included in this study, and further work may be 294 
required.  295 
 296 
Whilst pain is commonly reported as a barrier to physical activity in patients with 297 
Achilles tendinopathy, although significant improvements in pain were demonstrated in 298 
patients with both non-insertional and insertional Achilles tendinopathy, no consistent 299 
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benefits were recorded in rates of physical activity undertaken. It may be that further 300 
interventions are required to specifically increase rates of physical activity in this patient 301 
population. Due to the numerous health benefits from regular physical activity, this is an 302 
important area worthy of further consideration in future research. 303 
 304 
This study involved only small number of patients particularly with non-insertional 305 
Achilles tendinopathy, who have traditionally undergone different treatments in this 306 
hospital department in which this study was based. The follow-up period of this study 307 
was relatively short, and longer-term follow-up is required to assess any persisting 308 
benefits. Larger studies using similar outcome measures with longer follow up periods 309 
may be helpful to examine these areas in more detail. Furthermore, no specific record 310 
was kept as to analgesic use before/during/following procedure to see if this is reduced 311 
by the use of ESWT, this should be factored into further study designs to give more 312 
reliable marker of any benefit, and to take account of this possible confounding factor. 313 
 314 
It is hoped that this study can add to the gathering evidence suggesting benefit in 315 
the treatment of patients with recalcitrant Achilles tendinopathy, of both non-insertional 316 
and insertional variants. Furthermore, it is hoped that further discussion can be made to 317 
harmonise outcome measures used between different studies to give a more holistic 318 
view of patient functioning, and allow direct comparison across different domains for 319 
different studies, procedures, and conditions. The data from this study could be used to 320 
develop more robust study designs specifically to investigate the effectiveness of ESWT 321 
across different domains of patient function for patient Although causality of benefit 322 
cannot be shown from this study design, the results here are in keeping with other 323 
published evidence demonstrating a benefit from ESWT previously discussed with both 324 
insertional and non-insertional Achilles tendinopathy. 325 
 326 
 327 
 328 
 329 
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Table/s  342 
 343 
 344 
 345 
Outcome measure Assessing Scale Notes 
Victoria Institute of 
Sport Assessment – 
Achilles (VISA-A) 
Function of Achilles %scale Higher values 
indicate better 
function (but large 
weighting to activity 
score which may 
bias results against 
those not habitually 
active) 
Foot-Ankle Ability 
Measure (FAAM) 
%ADL 
Function of 
foot/ankle 
sub-score for 
activities of daily 
living displayed, 
%scale, range 0-
100% 
Higher score 
indicates better 
function 
painDETECT (pD) Potential markers of 
neuropathic pain 
0-38 Lower score 
suggests lower 
likelihood of 
neuropathic pain: (0-
12 = neuropathic 
pain unlikely, 13-18 
uncertain, 19-39  
neuropathic pain 
likely) 
EQ-5D-5L Global health status Health score 
displayed, range 0-
100% 
Higher score 
indicates better self-
rated global health 
Hospital Anxiety & 
Depression Scale 
Measure of anxiety 
and depression 
Anxiety & 
Depression sub-
Lower score 
indicates fewer 
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(HADS) symptoms scales, each range 
0-21 
symptoms 
International Physical 
Activity Questionnaire 
(IPAQ) – 7-day recall 
version 
Assessment of 
physical activity 
undertaken in the 
previous 7 days 
Scores of minutes 
of activity per week 
spent walking, in 
moderate activity, 
and in vigorous 
activity, and in 
hours of sitting on a 
weekday 
Increased levels of 
physical activity, or 
lower levels of 
sedentary behaviour, 
are associated with 
significant health 
benefits. 
    
Table 1: Patient-rated Outcome Measures (PROMs) used 346 
 347 
348 
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 349 
 350 
Figures are median 
(interquartile range) 
Insertional 
Achilles 
tendinopathy 
(n=30) 
Non-insertional 
Achilles 
tendinopathy 
(n=9) p-value 
%male 50% 44% 0.930 
age (years) 
55.4 
(46.4,60.6) 
46.3 
(40.3, 56.4) 
0.093 
Symptom duration in months 
21.0 
(12.0, 30.0) 
18.0 
(10.0, 24.0) 
0.544 
Self-reported “average” pain (0-
10 scale) 
6.5 
(5.0,7.8) 
7.0 
(7.0, 8.0) 
0.131 
Self-reported “worst” pain (0-10 
scale) 
8.0 
(7.0, 9.0) 
9.0 
(8.5, 9.0) 
0.100 
Self-reported “stiffness” (0-10 
scale) 
6.0 
(3.0, 7.0) 
7.0 
(3.0, 7.0) 
0.736 
PainDETECT 
15.0 
(13.3, 19.8) 
18.0 
(13.0, 20.0) 
0.949 
VISA-A 
28% 
(22%, 46%) 
24% 
(20%, 29%) 
0.248 
FAAM-ADL % 
57% 
(45%, 68%) 
55% 
(44%, 59%) 
0.592 
IPAQ – self-reported minutes of 
vigorous activity per week 
0 
(0,146) 
0 
(0, 30) 
0.736 
IPAQ - self-reported minutes of 
moderate activity per week 
15 
(0,68) 
0 
(0, 0) 
0.349 
IPAQ - self-reported minutes of 
walking per week 
300 
(28,840) 
75 
(14, 210) 
0.538 
IPAQ - self-reported hours of 
sitting on a typical weekday 
4.0 
(3.1, 6.6) 
4.0 
(4.0, 7.0) 
0.781 
“vital signs”- self-reported 
minutes of activity per week 
58 
(0, 188) 
10 
(0, 22) 
0.254 
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EQ-5D - % health 
70% 
(52%, 86%) 
60% 
(52%, 75%) 
0.433 
HAD – Anxiety sub-scale 
5.0 
(2.0, 7.5) 
7.0 
(3.0, 8.0) 
0.483 
HAD – Depression sub-scale 
3.0 
(1.5, 7.0) 
5.0 
(3.0, 9.0) 
0.263 
Table 2: Biographic and baseline PROMs data for subjects treated for insertional and non-351 
insertional Achilles tendinopathy symptoms. Figures are median (IQR) 352 
 353 
 354 
355 
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 356 
Insertional 
Achilles tendinopathy 
baseline  
(n=30) 
6-weeks 
(n=24) 
3-months 
(n=24) 
6-months 
(n=18) 
Self-reported “average 
pain” (0-10 scale) 
6.5 
(5.0,7.8) 
5.0 * 
(3.5, 5.0) 
3.5 * 
(2.0, 5.1) 
2.0 * 
(0.6, 4.8) 
Self-reported “worst 
pain” (0-10 scale) 
8.0 
(7.0, 9.0) 
6.5 * 
(5.3, 7.4) 
5.8 * 
(3.0, 7.0) 
5.0 * 
(3.0, 6.0) 
Self-reported “stiffness” 
(0-10 scale) 
6.0 
(3.0, 7.0) 
3.8 * 
(3.0, 6.0) 
3.0 * 
(2.0, 6.0) 
3.0 * 
(1.0, 4.8) 
PainDETECT 
15.0 
(13.3, 19.8) 
13.0 
(10.5, 16.0) 
10.5 * 
(8.0, 17.3) 
9.5 * 
(6.5, 12.3) 
VISA-A 
28% 
(22%, 46%) 
48% * 
(32%, 64%) 
55% * 
(42%, 68%) 
60% * 
(49%, 73%) 
FAAM-ADL % 
57% 
(45%, 68%) 
68% * 
(52%, 82%) 
71% * 
(62%, 91%) 
85% * 
(73%, 94%) 
IPAQ – self-reported 
minutes of vigorous 
activity per week 
0 
(0,146) 
60 
(0, 240) 
0 
(0, 135) 
110 
(0, 293) 
IPAQ - self-reported 
minutes of moderate 
activity per week 
15 
(0,68) 
80 
(0, 180) 
90 * 
(0, 330) 
60 * 
(0, 255) 
IPAQ - self-reported 
minutes of walking per 
week 
300 
(28,840) 
360 
(105, 840) 
390 
(90, 855) 
390 
(210, 735) 
IPAQ - self-reported 
hours of sitting on a 
typical weekday 
4.0 
(3.1, 6.6) 
4.5 
(3.0, 8.0) 
4.0 
(3.0, 6.0) 
4.0 
(3.0, 8.0) 
“vital signs”- self-
reported minutes of 
activity per week 
58 
(0, 188) 
160 
(80, 270) 
100 
(0,248) 
65 
(0, 158) 
EQ-5D - % health 
70% 
(52%, 86%) 
70% 
(60%, 85%) 
78% 
(70%, 80%) 
85% 
(78%, 95%) 
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HAD – Anxiety sub-scale 
5.0 
(2.0, 7.5) 
4.0 
(1.8, 8.0) 
5.0 
(2.5, 7.0) 
3.0 
(1.8, 5.3) 
HAD – Depression sub-
scale 
3.0 
(1.5, 7.0) 
3.5 
(1.8, 4.3) 
3.0 
(1.5, 4.0) 
2.0 
(1.0, 3.0) 
Table 3: Displaying PROMs data for subjects with insertional Achilles tendinopathy at baseline 357 
and follow-up periods. Figures are median (IQR) (* = change from baseline reached statistical 358 
significance (p<0.05) but absolute values not displayed for clarity) 359 
 360 
 361 
362 
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 363 
Non-insertional 
Achilles tendinopathy 
baseline  
(n=9) 
6-weeks 
(n=6) 
3-months 
(n=9) 
6-months 
(n=4) 
Self-reported “average 
pain” (0-10 scale) 
7.0 
(7.0, 8.0) 
6.0 
(5.6, 6.8) 
6.0 
(3.0, 7.0) 
6.0 
(3.8, 7.0) 
Self-reported “worst 
pain” (0-10 scale) 
9.0 
(8.5, 9.0) 
7.0 
(5.9, 7.8) 
8.0 * 
(5.0, 8.0) 
8.5 
(6.5, 9.3) 
Self-reported “stiffness” 
(0-10 scale) 
7.0 
(3.0, 7.0) 
5.0 
(3.3, 6.4) 
6.0 
(4.0, 6.5) 
3.0 
(1.5, 5.0) 
PainDETECT 
18.0 
(13.0, 20.0) 
15.5 
(12.8, 16.0) 
14.0 
(5.0, 19.0) 
14.5 
(9.8, 17.5) 
VISA-A 
24% 
(20%, 29%) 
38% 
(36%, 40%) 
44% * 
(39%, 48%) 
33% 
(26%, 46%) 
FAAM-ADL % 
55% 
(44%, 59%) 
56% 
(43%, 60%) 
60% 
(48%, 76%) 
71% 
(61%, 84%) 
IPAQ – self-reported 
minutes of vigorous 
activity per week 
0 
(0, 30) 
5 
(0, 115) 
20 
(0, 36) 
0 
(0, 5) 
IPAQ - self-reported 
minutes of moderate 
activity per week 
0 
(0, 0) 
5 
(0, 25) 
12 
(0, 30) 
0 
(0, 15) 
IPAQ - self-reported 
minutes of walking per 
week 
75 
(14, 210) 
15 
(0, 165) 
60 
(16, 350) 
220 
(162, 390) 
IPAQ - self-reported 
hours of sitting on a 
typical weekday 
4.0 
(4.0, 7.0) 
5.5 
(2.8, 6.0) 
6.0 
(4.0, 8.0) 
6.8 
(5.3, 8.0) 
“vital signs”- self-
reported minutes of 
activity per week 
10 
(0, 22) 
14 
(0, 120) 
30 
(0, 44) 
20 
(0, 65) 
EQ-5D - % health 
60% 
(52%, 75%) 
73% 
(62%, 79%) 
70% 
(50%, 78%) 
60% 
(50%, 69%) 
HAD – Anxiety sub-scale 7.0 6.0 7.0 7.5 
 20 
(3.0, 8.0) (3.8, 7.5) (4.0, 8.0) (4.5, 9.8) 
HAD – Depression sub-
scale 
5.0 
(3.0, 9.0) 
4.5 
(0.5, 8.5) 
6.0 
(3.0, 7.0) 
8.5 
(4.5, 11.8) 
Table 4: Displaying PROMs data for subjects with non-insertional Achilles tendinopathy at 364 
baseline and follow-up periods. Figures are median (IQR) (* = change from baseline reached 365 
statistical significance (p<0.05) but absolute p-values not displayed for clarity) 366 
 367 
 368 
369 
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 370 
Change in values from 
baseline to 3-months 
Insertional 
Achilles 
tendinopathy 
(n=24) 
Non-insertional 
Achilles 
tendinopathy 
(n=9) p-value 
Self-reported “average” 
pain (0-10 scale) 
2.0 
(1.0, 3.3) 
1.0 
(0.0, 4.0) 
0.437 
Self-reported “worst” pain 
(0-10 scale) 
2.0 
(0.5, 4.0) 
1.0 
(0.0, 2.0) 
0.301 
Self-reported “stiffness” 
(0-10 scale) 
2.0 
(-0.8, 3.0) 
1.0 
(0.0, 1.5) 
0.363 
PainDETECT 
4.0 
(2.0, 7.0) 
1.5 
(1.0, 5.0) 
0.220 
VISA-A 
23% 
(0%, 43%) 
11% 
(7%, 22%) 
0.617 
FAAM-ADL % 
12% 
(1%, 27%) 
12% 
(-7%, 23%) 
0.699 
Table 5: Displaying change in PROMs data for subjects with insertion and non-insertional 371 
Achilles tendinopathy from baseline to three-month follow-up periods. (Positive figure indicating 372 
improvement, negative figure indicating deterioration in condition. Significance figures 373 
calculating difference between the two groups) Figures are median (IQR) 374 
 375 
376 
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 377 
 378 
Roles & 
Maudsley 
score 
Insertional Achilles 
tendinopathy 
Non-insertional Achilles 
tendinopathy 
p-value 
6-weeks 
3.0 
(2.0, 3.0) 
3.0 
(2.3, 3.0) 
1.000 
3-months 
3.0 
(2.0, 3.0) 
3.0 
(2.0, 4.0) 
0.359 
6-months 
2.0 
(1.0, 3.0) 
3.5 
(3.0, 4.0) 
0.228 
Table 6: Displaying Roles & Maudsley score at each follow-up time point comparing results for 379 
subjects with insertional and non-insertional Achilles tendinopathy. Figures are median (IQR) 380 
381 
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